Research Analysts Issue Forecasts for SLNO FY2025 Earnings

Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for Soleno Therapeutics in a report released on Thursday, May 8th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($3.44) for the year, down from their prior estimate of ($2.85). Cantor Fitzgerald currently has a "Overweight" rating and a $123.00 price target on the stock. The consensus estimate for Soleno Therapeutics' current full-year earnings is ($3.72) per share.

Several other equities analysts have also issued reports on the company. Piper Sandler boosted their price target on Soleno Therapeutics from $93.00 to $145.00 and gave the company an "overweight" rating in a research note on Thursday, April 24th. Stifel Nicolaus boosted their price target on Soleno Therapeutics from $74.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, March 28th. Lifesci Capital raised Soleno Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 4th. UBS Group set a $105.00 price target on Soleno Therapeutics in a research note on Thursday, March 27th. Finally, Laidlaw boosted their price target on Soleno Therapeutics from $75.00 to $105.00 and gave the company a "buy" rating in a research note on Thursday, March 27th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $106.78.

Soleno Therapeutics Price Performance

Shares of Soleno Therapeutics stock traded up $0.15 during midday trading on Monday, reaching $75.22. The company had a trading volume of 102,948 shares, compared to its average volume of 740,067. The stock has a fifty day moving average price of $65.68 and a 200 day moving average price of $54.93. The firm has a market cap of $3.79 billion, a PE ratio of -22.65 and a beta of -2.67. Soleno Therapeutics has a fifty-two week low of $36.93 and a fifty-two week high of $80.99.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.95) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.19.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of SLNO. Barclays PLC grew its stake in Soleno Therapeutics by 149.3% in the 3rd quarter. Barclays PLC now owns 52,545 shares of the company's stock valued at $2,652,000 after purchasing an additional 31,467 shares during the period. JPMorgan Chase & Co. grew its stake in Soleno Therapeutics by 35.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 13,915 shares of the company's stock valued at $703,000 after purchasing an additional 3,666 shares during the period. Harbor Capital Advisors Inc. grew its stake in Soleno Therapeutics by 3.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 37,296 shares of the company's stock valued at $1,676,000 after purchasing an additional 1,248 shares during the period. Avanza Fonder AB purchased a new position in shares of Soleno Therapeutics during the 4th quarter valued at $76,000. Finally, Avior Wealth Management LLC purchased a new position in shares of Soleno Therapeutics during the 4th quarter valued at $89,000. Institutional investors own 97.42% of the company's stock.

Insider Buying and Selling

In related news, CEO Bhatnagar Anish sold 699,095 shares of the company's stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $67.62, for a total transaction of $47,272,803.90. Following the completion of the sale, the chief executive officer now owns 577,076 shares in the company, valued at approximately $39,021,879.12. This represents a 54.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Patricia C. Hirano sold 128,653 shares of the company's stock in a transaction on Thursday, March 27th. The stock was sold at an average price of $68.32, for a total value of $8,789,572.96. Following the sale, the insider now owns 55,789 shares of the company's stock, valued at $3,811,504.48. This trade represents a 69.75% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 942,672 shares of company stock worth $64,058,781. 12.30% of the stock is owned by corporate insiders.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.